Insider Trading History of Berelowitz Michael

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Berelowitz Michael since 2014. The trader's CIK number is 1493383. At the time of the last reporting, Berelowitz Michael was the Officer of Recro Pharma, Inc.. (stock ticker symbol REPH). Also see all insider trading activities at Recro Pharma, Inc..

Note that in the past Berelowitz Michael also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Recro Pharma, Inc. (REPH) by Berelowitz Michael

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2018 REPH 0 $0 7,500 $78,345 20,774 $18,525

Yearly summary of insider trading at Oramed Pharmaceuticals Inc. (ORMP) by Berelowitz Michael

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 ORMP 0 $0 2,000 $17,917 0 $0
2014 ORMP 0 $0 9,434 $99,057 9,434 $46,415


Insider trading activities at 2 companies by Berelowitz Michael:

1. Recro Pharma, Inc. (REPH)

2. Oramed Pharmaceuticals Inc. (ORMP)

Table 1. Insider trading of Recro Pharma, Inc. (REPH) by Berelowitz Michael

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2018-05-12 REPH Option Ex 13,274 .00 0
2018-03-09 REPH Option Ex 7,500 2.47 18,525
2018-03-09 REPH Sale 7,500 10.45 78,345

Table 2. Insider trading of Oramed Pharmaceuticals Inc. (ORMP) by Berelowitz Michael

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-12-09 ORMP Sale 700 9.44 6,608
2015-12-07 ORMP Sale 539 8.70 4,689
2015-12-08 ORMP Sale 761 8.70 6,620
2014-03-31 ORMP Sale 9,434 10.50 99,057
2014-03-31 ORMP Option Ex 9,434 4.92 46,415

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Berelowitz Michael (Officer of Recro Pharma, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.